SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies surges on getting USFDA’s approval for Lacosamide Injection

08 Apr 2022 Evaluate

Indoco Remedies is currently trading at Rs. 397.70, up by 4.90 points or 1.25% from its previous closing of Rs. 392.80 on the BSE.

The scrip opened at Rs. 394.90 and has touched a high and low of Rs. 399.00 and Rs. 383.95 respectively. So far 9307 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 529.70 on 12-Aug-2021 and a 52 week low of Rs. 296.75 on 08-Apr-2021.

Last one week high and low of the scrip stood at Rs. 400.50 and Rs. 377.75 respectively. The current market cap of the company is Rs. 3633.03 crore.

The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 19.40% and 21.91% respectively.

Indoco Remedies has received an approval from the United States Food & Drug Administration (USFDA) for ANDA Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials. The generic Lacosamide Injection USP of the company is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vimpat Injection of UCB, Inc.

Lacosamide injection is indicated for the prevention and control of seizures. It is an anticonvulsant/ antiepileptic drug. According to available IQVIA, sales data for Vimpat Injection is approximately $43.8 million, growing at 25%.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×